Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palbociclib - Chia Tai Tianqing Pharmaceutical

Next Previous
X
Search
Drug Profile

Palbociclib - Chia Tai Tianqing Pharmaceutical

Alternative Names: TQB-3616

Latest Information Update: 18 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HER2 negative breast cancer
  • Phase II Lung cancer

Most Recent Events

  • 29 Nov 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase-I trial (In volunteers) in China (PO) (NCT06149611)
  • 30 Mar 2023 Phase-III clinical trials in HER2-negative-breast-cancer (Adjuvant therapy, Combination therapy) in China (PO) (NCT05780567)
  • 22 Mar 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase III trial for HER2-negative-breast-cancer (Adjuvant therapy, Combination therapy) in China in March 2023 (PO, Capsule) (NCT05780567)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top